Intellipharmaceutics International Inc. (IPCI)

[WeeZuhl]

Weasel- Here is what you said exactly:

I have said the opposite of that. I have said the IPCI wants to be sued by Purdue, since a successful Paragraph IV patent challenge is the only clear path around OxyContin's Pediatric Exclusivity, based on the Hatch-Waxman Act. Purdue's best course of action is to do nothing and let the FDA block Rexista until at least August 2018.

OK you were wrong... Now you are saying what?

What has happened that makes that wrong? IPCI wanted to be sued, and they got sued. Good for them. Now they have to win in court, and if they do, they get a free pass around OxyContin's Pediatric Exclusivity. Every word of it is still correct and remains valid, so I have no idea what you're talking about. I still think Purdue would have been better served by doing nothing, but I don't work for Purdue.